ADIENNE is developing a portfolio of antibody drug conjugates (ADC) with the monoclonal antibody Begelomab® and toxins through various conjugation strategies to treat blood diseases, with a particular focus on acute T-cell lymphoblastic leukemia (T-ALL). Compared to traditional chemotherapy the antibody-based molecular platform enables selective delivery of a potent cytotoxic payload to target cancer cells, resulting in improved efficacy, reduced systemic toxicity, more favourable pharmacokinetics and pharmacodynamics properties and improved biodistribution.
